A comparative analysis of the efficacy of HAART with TDF and with AZT
10.3969/j.issn.1006-5725.2015.09.029
- VernacularTitle:含替诺福韦或齐多夫定的高效抗逆转录病毒治疗方案的疗效比较和耐药分析
- Author:
Zhenzhen LU
;
Qijian SU
;
Xuan LI
;
Linchun FU
- Publication Type:Journal Article
- Keywords:
Acquired immunodeficiency syndrome;
HAART;
TDF;
AZT;
Efficacy;
Drug resistance
- From:
The Journal of Practical Medicine
2015;(9):1475-1478
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy of highly active anti-retroviral treatment (HAART) with and with AZT. Methods Data of 235 HIV patients accepted from Oct. 2010 to Nov. 2013 who took AZT (133) or TDF (102) containing regimen as first-line HAART are analyzed retrospectively. CD4+ T cell counts acted as the base line after 12 months of HAART. Increase in CD4+ T cell count number after the HAART, virological failures and drug resistance were compared between the two groups. Results The two groups had comparable baseline CD4+T cell count, gender ratio, and HIV transmision mode; after 12 months of HARRT, no statistically differences were found between the two groups with regard to CD4 + T cell count and increase in CD4+ T cell count after the 12-month HAART (P > 0.05); AZT-containing group had more virological failure (3/0). Meanwhile AZT-containing group had one thymidine analog mutation (TAMs) which confers resistance to AZT (P > 0.05 for both). Conculsion The two HAARTs have same immunological effects; AZT-containing group exhibits 2.2% viralogial failure, but its direct relationship with AZT has not been confirmed.
